In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can ...

Only two in five people taking GLP-1 medication were confident they would maintain their weight loss after stopping the ...

People taking new weight-loss drugs say they curb cravings for booze, drugs, and nicotine. Did scientists inadvertently ...

Allurion's new program uses artificial intelligence guidance to help patients adhere to a well-rounded diet and exercise ...

According to the independent research and polling source KFF, one in eight Americans reported taking a GLP-1 receptor agonist ...

In 2020, West Virginia started a pilot program providing subsidies for GLP-1 weight loss drugs for state employees. It showed ...

The likes of Wegovy and Ozempic could reduce the risk of kidney deterioration and failure by a fifth, a major study found.